Plant Compound Epiberberine Tames Gut Inflammation by Fixing Bile Acid Recycling
A natural alkaloid from traditional Chinese medicine activates a key bile acid receptor to restore intestinal balance and reduce colitis inflammation.
Summary
Epiberberine, an alkaloid derived from Coptidis Rhizoma (a traditional Chinese herb), was found to significantly reduce ulcerative colitis (UC) severity in mouse models by targeting the farnesoid X receptor (FXR) in the intestine. UC is associated with disrupted bile acid metabolism, causing toxic bile acid accumulation in the gut that amplifies inflammation. Epiberberine directly binds FXR protein, boosting bile acid transporter expression and FGF15 signaling, which accelerates bile acid reabsorption and curbs excess synthesis. This reduces intestinal bile acid buildup and suppresses key inflammatory markers including NF-κB, IL-1β, and IL-6. When FXR was genetically deleted in mice, epiberberine lost its bile-acid-regulating and anti-inflammatory effects, confirming FXR as the primary target.
Detailed Summary
Ulcerative colitis is a chronic, relapsing inflammatory bowel disease affecting millions worldwide, with gut microbiome disruption and bile acid dysregulation increasingly recognized as central drivers of disease severity. Excess bile acid accumulation in the intestinal lumen is both a symptom and an amplifier of intestinal inflammation, making bile acid homeostasis a promising therapeutic target.
Researchers at Southwest University in Chongqing investigated epiberberine, one of the primary alkaloids found in the traditional Chinese herb Coptidis Rhizoma, for its potential to modulate bile acid metabolism and reduce colitis. Using UC mouse models and cell-based assays, they examined whether epiberberine's effects depend on activation of the intestinal farnesoid X receptor (FXR), a nuclear receptor that governs bile acid synthesis, transport, and recycling.
The study found that epiberberine directly binds FXR with meaningful affinity (KD = 2.04 μmol/L), with two specific amino acid residues — MET265 and ARG331 — identified as critical binding sites via molecular docking and mutagenesis experiments. Upon binding, FXR activation upregulated bile acid transporters OSTα, OSTβ, and IBABP, and stimulated secretion of FGF15, a gut hormone that signals the liver to reduce bile acid synthesis. The net result was reduced intestinal bile acid accumulation and measurably lower expression of pro-inflammatory proteins NF-κB, IL-1β, and IL-6.
Crucially, in FXR-knockout mice, epiberberine's ability to regulate bile acids and attenuate colitis was substantially abolished, providing strong mechanistic confirmation that FXR is the primary molecular target.
These findings position epiberberine as a novel FXR agonist with dual anti-inflammatory and bile acid-normalizing activity. Caveats include the exclusively preclinical nature of this research and that only abstract-level data are currently available for review, limiting assessment of full statistical rigor.
Key Findings
- Epiberberine directly binds intestinal FXR protein with a binding affinity of KD = 2.04 μmol/L.
- FXR activation by epiberberine upregulates bile acid transporters OSTα, OSTβ, IBABP and increases FGF15 secretion.
- Treatment reduced intestinal bile acid accumulation and lowered NF-κB, IL-1β, and IL-6 inflammatory markers in UC mice.
- FXR-knockout mice lost the bile-acid-regulating and anti-colitis benefits, confirming FXR as the essential target.
- Key binding residues MET265 and ARG331 on FXR were identified via molecular docking and site-directed mutagenesis.
Methodology
The study used DSS-induced UC mouse models, in vitro cell assays, and multiple protein-binding techniques (CETSA, SIP, DARTS, IP-MS, ITC) to confirm direct epiberberine-FXR interaction. Wild-type and Fxr-/- knockout mice were compared to validate FXR as the functional target in vivo. Molecular docking and site-directed mutagenesis pinpointed specific FXR binding residues.
Study Limitations
This research is entirely preclinical, conducted in mouse models and cell lines, with no human clinical data yet available. Only the abstract was accessible, limiting evaluation of full statistical methodology, sample sizes, and dose-response data. Translation to human UC is uncertain given interspecies differences in bile acid composition and FXR biology.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.